Riociguat is one of several approved therapies available for patients with pulmonary arterial hypertension (PAH). Treatment should be initiated and monitored at an expert center by a physician experienced in treating PAH, and the dose adjusted in the absence of signs and symptoms of hypotension. In certain populations, including patients with hepatic or renal impairment, the elderly, and smokers, riociguat exposure may differ, and dose adjustments should therefore be made with caution according to the established scheme. Common adverse events are often easily managed, particularly if they are discussed before starting therapy. Combination therapy with riociguat and other PAH-targeted agents is feasible and generally well tolerated, although the coadministration of phosphodiesterase type 5 inhibitors (PDE5i) and riociguat is contraindicated. An open-label, randomized study is currently ongoing to assess whether patients who do not achieve treatment goals while receiving PDE5i may benefit from switching to riociguat. In this review, we provide a clinical view on the practical management of patients with PAH receiving riociguat, with a focus on the opinions and personal experience of the authors. The reviews of this paper are available via the supplemental material section.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710674 | PMC |
| http://dx.doi.org/10.1177/1753466619868938 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Redefining supplier selection in healthcare sector: a novel framework for supplier classification.
J Health Organ Manag
January 2025
Amrita School of Business - Amritapuri Kollam Campus, Kollam, India.
Purpose: This paper aims to delve into the critical aspect of supplier selection in the healthcare sector, emphasizing the significance of strategic sourcing in enhancing operational efficiency and quality of services. The primary aim is to develop a comprehensive framework for supplier evaluation that aligns with the unique requirements of hospitals, ultimately improving procurement processes and patient care outcomes.
Design/methodology/approach: The study leverages the renowned Carter's 7 C model as a foundational framework for supplier assessment, supplemented by insights gathered from interviews with experts in the New Product Introduction, Purchasing and Procurement departments of a leading hospital in India.
Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety.
Curr Obes Rep
January 2025
CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Purpose Of Review: The present review describes the available literature on the physiologic mechanisms that modulate hunger, appetite, satiation, and satiety with a particular focus on well-established and emerging factors involved in the classic satiety cascade model.
Recent Finding: Obesity is a significant risk factor for numerous chronic conditions like cancer, cardiovascular diseases, and diabetes. As excess energy intake is considered by some to be the primary driver of weight gain, tremendous collective effort should be directed toward reducing excessive feeding at the individual and population levels.
Risk of hospital inpatient opioid overdose (RHINOO): a review of factors impacting naloxone administration in patients receiving opioids.
Eur J Clin Pharmacol
January 2025
Department of the Acute Pain Service, St. Luke's University Health Network, 801 Ostrum St, Bethlehem, PA, 18015, USA.
Purpose: Opioid medications remain a common treatment for acute pain in hospitalized patients. This study aims to identify factors contributing to opioid overdose in the inpatient population, addressing the gap in data on which patients are at higher risk for opioid-related adverse events in the hospital setting.
Methods: A retrospective chart review of inpatients receiving at least one opioid medication was performed at a large academic medical center from January 1, 2022, through December 31, 2022.
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
Ann Hematol
January 2025
Service de Thérapie Cellulaire et d'Hématologie Clinique, CHU Estaing, Clermont-Ferrand, France.
The advent of BTK inhibitors has been transformative in the management of patients with chronic lymphocytic leukemia or other B-cell lymphoproliferative disorders. However, emergence of BTK or PLCG2 mutations lead to resistance to these compounds and are now a growing concern in clinical practice. Assessing BTK mutations is now becoming a priority to guide the therapeutic decision at further relapse.
View Article and Find Full Text PDFGlucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes.
Diabetologia
January 2025
MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Aims/hypothesis: UK standard care for type 2 diabetes is structured diabetes education, with no effects on HbA, small, short-term effects on weight and low uptake. We evaluated whether remotely delivered tailored diabetes education combined with commercial behavioural weight management is cost-effective compared with current standard care in helping people with type 2 diabetes to lower their blood glucose, lose weight, achieve remission and improve cardiovascular risk factors.
Methods: We conducted a pragmatic, randomised, parallel two-group trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!